Breast cancer trial halted after just 2 patients enrolled

NCT ID NCT02688803

Terminated Knowledge-focused Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to test a simpler consent process to compare three standard chemotherapy regimens for triple-negative breast cancer. Only 2 participants enrolled before the trial was terminated early, so it could not determine which treatment works best. The main goal was to see if this new consent model was feasible, not to find a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, 5-FU, epirubicin, docetaxel)
What this could lead to: If successful, this approach could make it easier to compare standard treatments in real-world settings, helping doctors choose the best chemotherapy for triple-negative breast cancer.
What could go wrong: The trial was terminated early with only 2 participants, so it did not gather enough data to draw meaningful conclusions. The results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The Ottawa Hospital Cancer Centre

Ottawa, Ontario, K2H 8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.